- Home
- RNA
as 06-13-2025 11:41am EST
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 3.4B | IPO Year: | 2020 |
| Target Price: | $69.00 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.03 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.51 - $56.00 | Next Earning Date: | 08-08-2025 |
| Revenue: | $8,927,000 | Revenue Growth: | -17.88% |
| Revenue Growth (this year): | -43.29% | Revenue Growth (next year): | 155.06% |
Stock Insider Trading Activity of Avidity Biosciences Inc. (RNA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Gallagher Kathleen P. | RNA | Chief Program Officer | Jun 2 '25 | Sell | $32.48 | 5,875 | $190,832.93 | 50,554 | |
| Gallagher Kathleen P. | RNA | Chief Program Officer | May 1 '25 | Sell | $32.40 | 5,875 | $190,324.15 | 50,554 | |
| Gallagher Kathleen P. | RNA | Chief Program Officer | Apr 1 '25 | Sell | $27.83 | 5,875 | $163,485.98 | 50,554 | |
| Boyce Sarah | RNA | President and CEO | Mar 20 '25 | Sell | $31.06 | 31,540 | $979,563.01 | 305,871 | |
| MacLean Michael F | RNA | Chief Financial Officer | Mar 20 '25 | Sell | $31.06 | 7,935 | $246,424.60 | 96,720 | |
| Flanagan W. Michael | RNA | Chief Scientific Officer | Mar 20 '25 | Sell | $31.06 | 11,780 | $365,867.95 | 80,195 | |
| McCarthy Teresa | RNA | Chief Human Resources Officer | Mar 20 '25 | Sell | $31.06 | 7,778 | $241,583.12 | 97,130 | |
| Hughes Steven George | RNA | Chief Medical Officer | Mar 20 '25 | Sell | $31.06 | 9,578 | $297,490.76 | 72,850 |
Latest Avidity Biosciences Inc. News
RNA Breaking Stock News: Dive into RNA Ticker-Specific Updates for Smart Investing
Insider Monkey
2 days ago
Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James
Investing.com
2 days ago
Raymond James bullish on biotech firms on favorable valuation
PR Newswire
2 days ago
Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress
TipRanks
3 days ago
Avidity Biosciences price target raised to $75 from $65 at Chardan
Benzinga
4 days ago
Avidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease Trial
PR Newswire
4 days ago
Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants
PR Newswire
4 days ago
Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD
Yahoo Finance
13 days ago
This week in Trumponomics: Too bad TACO isn’t true
Compare RNA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RNA Avidity Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.